Brezu Adverse Reactions

Japanese Data: In clinical trials involving 22,757 subjects, a total of 644 patients (2.83%) showed adverse reactions including abnormal laboratory values. The following summary of data includes adverse reactions reported after marketing without incidence.
Clinically significant adverse reactions (incidence unknown*): Shock, Anaphylactoid Reaction: Shock or anaphylactoid reaction may occur. Patients should therefore be closely monitored. If abnormal findings are observed, the drug should be discontinued and appropriate measures should be taken.
Significant decreases in serum potassium levels have been reported in patients receiving procaterol hydrochloride.
If xanthine derivatives, corticosteroids or diuretics are co-administered with Brezu in patients with severe asthma, extreme care is necessary to minimize the possibility of aggravating the decrease in serum potassium levels induced by β₂-adrenergic agonists. Serum potassium levels should be closely monitored in hypoxic patients, in view of the possible aggravation of cardiac arrhythmias secondary to a decrease in serum potassium levels.
Other Adverse Reactions: See Table 3.

Click on icon to see table/diagram/image